Photo by atikahakhtar from unsplash
Hereditary angioedema (HAE) due to C1‐inhibitor deficiency (C1‐INH‐HAE) is a rare, potentially fatal, bradykinin‐mediated disease. Icatibant is a bradykinin B2 receptor antagonist originally approved in 2008 in the European Union… Click to show full abstract
Hereditary angioedema (HAE) due to C1‐inhibitor deficiency (C1‐INH‐HAE) is a rare, potentially fatal, bradykinin‐mediated disease. Icatibant is a bradykinin B2 receptor antagonist originally approved in 2008 in the European Union and 2011 in the United States as an acute therapy option for HAE attacks in adults.
Keywords:
experience hereditary;
hereditary angioedema;
outcome survey;
icatibant outcome;
angioedema;
survey experience
Journal Title: Journal of the European Academy of Dermatology and Venereology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of the European Academy of Dermatology and Venereology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!